Literature DB >> 17379198

Free radical scavenging reactions and antioxidant activity of embelin: biochemical and pulse radiolytic studies.

Ravi Joshi1, J P Kamat, Tulsi Mukherjee.   

Abstract

Embelin (from Embelia ribes) is a component of herbal drugs and possess wide range of medicinal properties. These properties may be, in part, due to scavenging of oxidizing free radicals. In this context, free radical scavenging reactions and antioxidant activity of embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone) have been studied. It has been found to scavenge DPPH radical and inhibit hydroxyl radical induced deoxyribose degradation. It has been also found to inhibit lipid peroxidation and restore impaired Mn-superoxide dismutase in rat liver mitochondria. Further, kinetics and mechanism of the reactions of embelin with hydroxyl, one-electron oxidizing, organo-haloperoxyl and thiyl radicals have been studied using nanosecond pulse radiolysis technique. Its redox potential has been also evaluated with cyclic voltammetry. These studies suggest that embelin can act as a competitive antioxidant in physiological conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379198     DOI: 10.1016/j.cbi.2007.02.004

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  17 in total

1.  Protective effect of embelin from Embelia ribes Burm. against transient global ischemia-induced brain damage in rats.

Authors:  B S Thippeswamy; P Nagakannan; B D Shivasharan; S Mahendran; V P Veerapur; S Badami
Journal:  Neurotox Res       Date:  2011-07-13       Impact factor: 3.911

2.  Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells.

Authors:  Rong Hu; Ke Zhu; Yingchun Li; Kun Yao; Rong Zhang; Huihan Wang; Wei Yang; Zhuogang Liu
Journal:  Med Oncol       Date:  2010-07-13       Impact factor: 3.064

3.  Protective effects of embelin on myocardial ischemia-reperfusion injury following cardiac arrest in a rabbit model.

Authors:  Zhi-Gang Zhao; Zhong-Zhi Tang; Wen-Kai Zhang; Jian-Guo Li
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

4.  Embelin Reduces Systemic Inflammation and Ameliorates Organ Injuries in Septic Rats Through Downregulating STAT3 and NF-κB Pathways.

Authors:  Xian-Long Zhou; Lei Huang; Jun Cao
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

5.  Embelin attenuates adipogenesis and lipogenesis through activating canonical Wnt signaling and inhibits high-fat diet-induced obesity.

Authors:  Y Gao; J Li; X Xu; S Wang; Y Yang; J Zhou; L Zhang; F Zheng; X Li; B Wang
Journal:  Int J Obes (Lond)       Date:  2017-02-06       Impact factor: 5.095

6.  XIAP inhibitor Embelin inhibits bladder cancer survival and invasion in vitro.

Authors:  X Fu; X Pang; H Qi; S Chen; Y Li; W Tan
Journal:  Clin Transl Oncol       Date:  2015-07-25       Impact factor: 3.405

7.  Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis.

Authors:  Ting Wu; Chaohui Wang; Weihong Wang; Yuhang Hui; Rongxin Zhang; Liang Qiao; Yun Dai
Journal:  Oncoimmunology       Date:  2018-08-24       Impact factor: 8.110

8.  Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.

Authors:  Nupur Nigam; Abhinav Grover; Sukriti Goyal; Shashank P Katiyar; Priyanshu Bhargava; Pi-Chao Wang; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

9.  Embelin-induced apoptosis of HepG2 human hepatocellular carcinoma cells and blockade of HepG2 cells in the G2/M phase via the mitochondrial pathway.

Authors:  Asaf Taghiyev; Deguang Sun; Zhen Ming Gao; Rui Liang; Liming Wang
Journal:  Exp Ther Med       Date:  2012-07-11       Impact factor: 2.447

10.  Embelin-induced MCF-7 breast cancer cell apoptosis and blockade of MCF-7 cells in the G2/M phase via the mitochondrial pathway.

Authors:  Yang Li; Dalei Li; Shengguang Yuan; Zhenran Wang; Fang Tang; Rongrong Nie; Jun Weng; Lina Ma; Bo Tang
Journal:  Oncol Lett       Date:  2012-12-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.